June 23, 2021
New Horizons Forum unites key clinical, industry, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment. Each year, nationally and internationally respected pioneers in the fields of vision, business, and medical innovation come together to share insights, spark new ideas, and accelerate progress in glaucoma science, diagnostics, and therapies.
Implandata Ophthalmic Products has been presenting at New Horizons Forum since our inaugural meeting in 2012. The company has just obtained both FDA Breakthrough Device Designation and CE Mark for its EYEMATE system. Implandata announced in April that its EYEMATE system for digitally enabled remote patient monitoring and management of glaucoma has obtained Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Its EYEMATE-SC biosensor was CE Marked yesterday. The EYEMATE system is used for comprehensive remote glaucoma monitoring. It empowers patients with the ability to measure their intraocular pressures from anywhere and anytime, and then automatically send that information in real-time to their doctor.
Click the video below to watch Max Ostermeier’s presentation at the 2021 New Horizons Forum:
Qlaris Bio raises $25M for new glaucoma drug
Qlaris Bio, Inc. was founded in August 2019. Thurein Htoo, MS, MBA, CEO of Qlaris Bio, Inc. presented at the February 2020 New Horizons Forum in San Francisco during the session “Show Me the Money — Getting to Go in Early Stage Glaucoma Financing.” In April 2021, Qlaris annouced they were kicking off a phase 1/2 study of their new glaucoma treatment designed to lower episcleral venous pressure (EVP). They recently raised $25 million to get the new treatment, called QLS-101, through development. Click the video below to watch Thurein Htoo’s presentation at the 2020 New Horizons Forum:
Belkin Laser completes clinical trial enrollment
In July 2020, BELKIN Laser, the Israel-based start-up offering a 1-second, non-invasive glaucoma laser treatment announced that it finalized its round B financing of $12.25M. Last month, Belkin Laser announced that it has completed enrollment in its GLAUrious randomized controlled trial. In this confirmatory, prospective, noninferiority, observer masked RCT a total of 192 patients were randomized across two arms, SLT and DSLT. Six-month follow up for primary endpoint is expected in January of 2022 and 12-month follow up is expected in Q3 of 2022. The GLAUrious trial was supported with the EU Horizon 2020 grant. Belkin Laser’s CEO and co-founder Daria Lemann Blumenthal has presented multiple times at New Horizons Forum. Click the video below to watch Daria Lemann Blumenthal’s recorded presentation from the 2020 New Horizons Forum: